Skip to content

A Phase 1b Study to Characterize the Safety and Tolerability of TEV-53408 in Adults with Celiac Disease

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2022-502817-27-00
Acronym
TV53408-IMM-10197
Enrollment
6
Registered
2023-10-19
Start date
2024-03-15
Completion date
2025-10-08
Last updated
2025-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Celiac disease

Interventions

None listed

Sponsors

Teva Branded Pharmaceutical Products R&D LLC
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Countries

Finland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026